Обʼєднані Арабські Емірати - англійська - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

polysorbate 20 , sodium hyaluronate , dmdm hydantoin , lactic acid , benzoic acid , hydroxypropyl methylcellulose , ammonium glycyrrhizate -

Канада - англійська - Health Canada

id biomedical corporation of quebec - haemagglutinin-strain a (h5n1); squalene; polysorbate 80; vitamin e (dl-alpha tocopherol) - emulsion - 3.75mcg; 10.69mg; 4.86mg; 11.86mg - haemagglutinin-strain a (h5n1) 3.75mcg; squalene 10.69mg; polysorbate 80 4.86mg; vitamin e (dl-alpha tocopherol) 11.86mg - vaccines

США - англійська - NLM (National Library of Medicine)

vitaline s.a.c. - naphazoline hydrochloride (unii: mz1131787d) (naphazoline - unii:h231gf11bv), polysorbate 20 (unii: 7t1f30v5yh) (polysorbate 20 - unii:7t1f30v5yh) - naphazoline hydrocloride 0,03% redness reliever polysorbate 20 0,24% lubricant - you feel eye pain - changes in vision occur - redness or irritation of the eye lasts - condition worsens or lasts more than 72 hours relieves redness of the eye due to minor eye irritations

США - англійська - NLM (National Library of Medicine)

the mentholatum company - naphazoline hydrochloride (unii: mz1131787d) (naphazoline - unii:h231gf11bv), polysorbate 80 (unii: 6ozp39zg8h) (polysorbate 80 - unii:6ozp39zg8h) - naphazoline hydrochloride - redness reliever polysorbate 80 - lubricant - relieves redness of the eye due to minor eye irritations - temporarily relieves burning and irritation due to dryness of the eye

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 4 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - trastuzumab, quantity: 440 mg - injection, powder for - excipient ingredients: histidine hydrochloride; histidine; polysorbate 20; trehalose dihydrate - early breast cancer herzuma? is indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer herzuma? is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant herzuma?.,metastatic breast cancer herzuma? is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormonereceptor positive metastatic breast cancer.,advanced gastric cancer herzuma? is indicated in combination with cisplatin and either capecitabine or 5-fu for the treatment of patients with her2 positive advanced adenocarcinoma of the stomach or gastro- oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

США - англійська - NLM (National Library of Medicine)

innate pharma, inc. - moxetumomab pasudotox (unii: 2ndx4b6n8f) (moxetumomab pasudotox - unii:2ndx4b6n8f) - lumoxiti is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (hcl) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (pna). limitations of use lumoxiti is not recommended in patients with severe renal impairment (crcl ≤ 29 ml/min) [see dosage and administration (2.3), warnings and precautions (5.3), and use in specific populations (8.5)]. none. risk summary based on its mechanism of action and findings in non-pregnant female animals, lumoxiti is expected to cause maternal and embryo-fetal toxicity when administered to a pregnant woman [see clinical pharmacology (12.1) and nonclinical toxicology (13.2)] . there are no available data on lumoxiti use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. animal reproduction or developmental toxicity studies have not been conducted with lumoxiti. advise pregnant women of the potential risk to a fetus. the estimated background ris

США - англійська - NLM (National Library of Medicine)

hi-healthcare inc - hypromelloses     0.2% polysorbate 80     0.5% naphazoline hydrochloride     0.025% zinc sulfate     0.25% - hypromelloses      lubricant polysorbate 80      lubricant naphazoline hydrochloride      redness reliever zinc sulfate       astringent - for the temporary relief of discomfort and redness of the eye due to minor eye irritations. - for the temporary relief of burning & irritation due to dryness of the eye. - for protection against further irritation. • eye pain. • changes in vision. • continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 4 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.